However, this study assessed all patients with T2DM, regardless of their history or risk for ASCVD, to determine if SGLT2i or GLP-1 RA are prescribed according to a personalized approach and individual comorbidities. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.